Stock Alert: Lyra Therapeutics Tanks 20%

By RTTNews Staff Writer   ✉   | Published:

Shares of Lyra Therapeutics, Inc. (LYRA) are tanking over 20% on Monday morning despite positive topline results from phase 2 study of LYR-210 for chronic rhinosinusitis.

LYRA is currently trading at $9.55, down $2.92 or 23.42%, on the Nasdaq.

7500 mcg dose of LYR-210 achieved statistically significant improvement in a composite of the 4 cardinal symptoms of CRS at weeks 16, 20 and 24 compared to control.

"These data are yet more remarkable given it was achieved during the COVID-19 pandemic, which caused us to curtail enrollment sooner than originally planned," said Maria Palasis, CEO of Lyra Therapeutics.

The US stock market are down on Monday morning as investors are worried about rising coronavirus cases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google is considering whether to impose severe penalties on online conglomerate IAC/InterActive Corp. over alleged deceptive marketing practices, The Wall Street Journal reported. As per the report, Google determined that IAC misled users about its browser extensions, and the company could go as far as banning those products from its Chrome browser. Online payment services companies Mastercard and Visa Inc. are investigating allegations against Pornhub.com after a newspaper column accused the pornographic website of showing videos of child abuse, and rape, multiple reports said. Both credit card companies accept payments on the site. American Honda Motor Co., Inc., a unit of Japanese automaker Honda Motor Company, Ltd., has recalled recreational off-highway vehicles citing crash and injury risks, the U.S. Consumer Product Safety Commission said in a statement. The recall involves about 118,600 units of Honda Pioneer 700 & 1000 Recreational Off-Highway Vehicles or ROVs with Electric Power Steering or EPS.